Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil

Detalhes bibliográficos
Autor(a) principal: Colet, Christiane
Data de Publicação: 2018
Outros Autores: Amador, Tânia Alves, Heineck, Isabela
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/153876
Resumo: Warfarin is the most used anticoagulant in primary health care. Due to the narrow therapeutic index, its users are more susceptible to adverse events. The objective of this study was to describe the itinerary of the public health sector patients for resolution of adverse events related to warfarin. It is a prospective open cohort, held for a period of 18 months with warfarin users of the Brazilian public health system. Data were collected by monthly interviews and from patient records. Results: Sixty nine patients were interviewed, 64 of them completed monitoring and five died. Bleeding and venous thromboembolism were more frequent in patients starting treatment. It was observed that when adverse events have occurred, in most cases the patient held self-care at home (57%). During the follow-up, five patients were hospitalized for bleeding. Approximately half of the patients did not present their INR exams to the doctor. Conclusions: This study demonstrates weaknesses in caring for these patients and the need to accompany them, aiming to standardize and guide the itinerary of the anticoagulated patient to solve their problems and improve safety in drug treatment, with less cost to the public health system.
id USP-31_871a4a1c4ad601f5ba61b75244a4c302
oai_identifier_str oai:revistas.usp.br:article/153876
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern BrazilWarfarin/adverse drugCohort studiesHealth services accessibilityReactionBrazilWarfarin is the most used anticoagulant in primary health care. Due to the narrow therapeutic index, its users are more susceptible to adverse events. The objective of this study was to describe the itinerary of the public health sector patients for resolution of adverse events related to warfarin. It is a prospective open cohort, held for a period of 18 months with warfarin users of the Brazilian public health system. Data were collected by monthly interviews and from patient records. Results: Sixty nine patients were interviewed, 64 of them completed monitoring and five died. Bleeding and venous thromboembolism were more frequent in patients starting treatment. It was observed that when adverse events have occurred, in most cases the patient held self-care at home (57%). During the follow-up, five patients were hospitalized for bleeding. Approximately half of the patients did not present their INR exams to the doctor. Conclusions: This study demonstrates weaknesses in caring for these patients and the need to accompany them, aiming to standardize and guide the itinerary of the anticoagulated patient to solve their problems and improve safety in drug treatment, with less cost to the public health system.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2018-11-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/15387610.1590/s2175-97902018000317738Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 3 (2018); e17738Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 3 (2018); e17738Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 3 (2018); e177382175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/153876/150223Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessColet, ChristianeAmador, Tânia AlvesHeineck, Isabela2019-03-17T13:19:36Zoai:revistas.usp.br:article/153876Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2019-03-17T13:19:36Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil
title Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil
spellingShingle Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil
Colet, Christiane
Warfarin/adverse drug
Cohort studies
Health services accessibility
Reaction
Brazil
title_short Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil
title_full Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil
title_fullStr Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil
title_full_unstemmed Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil
title_sort Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil
author Colet, Christiane
author_facet Colet, Christiane
Amador, Tânia Alves
Heineck, Isabela
author_role author
author2 Amador, Tânia Alves
Heineck, Isabela
author2_role author
author
dc.contributor.author.fl_str_mv Colet, Christiane
Amador, Tânia Alves
Heineck, Isabela
dc.subject.por.fl_str_mv Warfarin/adverse drug
Cohort studies
Health services accessibility
Reaction
Brazil
topic Warfarin/adverse drug
Cohort studies
Health services accessibility
Reaction
Brazil
description Warfarin is the most used anticoagulant in primary health care. Due to the narrow therapeutic index, its users are more susceptible to adverse events. The objective of this study was to describe the itinerary of the public health sector patients for resolution of adverse events related to warfarin. It is a prospective open cohort, held for a period of 18 months with warfarin users of the Brazilian public health system. Data were collected by monthly interviews and from patient records. Results: Sixty nine patients were interviewed, 64 of them completed monitoring and five died. Bleeding and venous thromboembolism were more frequent in patients starting treatment. It was observed that when adverse events have occurred, in most cases the patient held self-care at home (57%). During the follow-up, five patients were hospitalized for bleeding. Approximately half of the patients did not present their INR exams to the doctor. Conclusions: This study demonstrates weaknesses in caring for these patients and the need to accompany them, aiming to standardize and guide the itinerary of the anticoagulated patient to solve their problems and improve safety in drug treatment, with less cost to the public health system.
publishDate 2018
dc.date.none.fl_str_mv 2018-11-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/153876
10.1590/s2175-97902018000317738
url https://www.revistas.usp.br/bjps/article/view/153876
identifier_str_mv 10.1590/s2175-97902018000317738
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/153876/150223
dc.rights.driver.fl_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 3 (2018); e17738
Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 3 (2018); e17738
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 3 (2018); e17738
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222913817739264